Zeria Pharmaceutical has been granted a patent for antibody molecules and functional fragments that bind to tumor necrosis factor alpha (TNFa). The patent details specific amino acid sequences for the variable light (VL) and variable heavy (VH) domains of these antibodies, outlining their therapeutic potential. GlobalData’s report on Zeria Pharmaceutical gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Zeria Pharmaceutical, Cancer treatment biomarkers was a key innovation area identified from patents. Zeria Pharmaceutical's grant share as of June 2024 was 45%. Grant share is based on the ratio of number of grants to total number of patents.
Antibody molecules targeting tumor necrosis factor alpha (tnfa)
The patent US12043663B2 describes a novel antibody or functional fragment that specifically binds to human tumor necrosis factor alpha (TNFa). The claims detail various structural configurations of the antibody, including specific amino acid sequences for the variable light (VL) and variable heavy (VH) domains, which are critical for its binding affinity. The patent outlines multiple embodiments of the antibody, including single-chain variable fragments (scFv) and immunoglobulin G (IgG). Additionally, the antibody demonstrates a high binding affinity to human TNFa, with a dissociation constant (KD) of less than 125 pM, and shows cross-reactivity with TNFa from Macaca fascicularis. The antibody's efficacy is further highlighted by its ability to inhibit TNFa-induced apoptosis more effectively than infliximab in specific assays.
Moreover, the patent encompasses methods for producing the antibody, including the use of nucleic acids encoding the antibody, vectors, and cultured cells for expression. It also claims a pharmaceutical composition that includes the antibody or its functional fragments, which can be combined with acceptable carriers or excipients. The therapeutic applications of this composition are aimed at treating inflammatory disorders, particularly those related to TNFa, such as inflammatory bowel disease, Crohn's disease, and ulcerative colitis. The claims emphasize the potential of this antibody in addressing various inflammatory conditions, providing a foundation for further research and development in therapeutic interventions targeting TNFa-related disorders.
To know more about GlobalData’s detailed insights on Zeria Pharmaceutical, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
